Novo Nordisk's GLP-1 pill shows blood-sugar reduction in teens with type 2 diabetes

Novo Nordisk reported results from a study evaluating its oral GLP-1 therapy, Rybelsus, in adolescents with type 2 diabetes.

The trial enrolled participants aged 10-17 who took the pill for roughly six months, and the analysis showed an average reduction of about 0.83 percentage points in HbA1c levels.

The reduction was statistically significant compared with baseline, indicating the medication can improve glycemic control in this younger population.

The findings suggest the oral formulation could expand treatment options for pediatric diabetes, though further data on long-term safety and regulatory steps were not detailed.